As part of our Meet the Expert series, Strategy Director Steven Robery interviews Dorothee Bartels, our expert in real-world data and evidence. Curious about how clinical pharmacology fits into your strategy? Get in touch to learn how our experts can give your drug the best chance of success in clinical trials.

As part of our ​'Meet the Expert' series, Strategy Director Steven Robery interviews Simon Hutchings, a Senior Clinical Pharmacologist at Weatherden. Curious about how clinical pharmacology fits into your strategy? Get in touch to learn how our experts can give your drug the best chance of success in clinical trials. 

As a paediatrician working in drug development, mother of a child with a rare disease, and founder of a medical research charity, Dr Harriet Holme understands the complexities of the rare disease landscape. Here, she argues that while balancing the interests of various stakeholders is essential, we cannot afford to delay action in the rare disease space any longer.

What does the US Inflation Reduction Act (IRA) mean for indication selection, and how could this alter lifecycle management? In the second instalment of this three-part series, Emma Tinsley, Chief Executive Officer of Weatherden, tells us about the key strategic considerations for biopharma companies in the post-IRA era.

What does the US Inflation Reduction Act (IRA) mean for indication selection, and how could this alter lifecycle management? In the second instalment of this three-part series, Emma Tinsley, Chief Executive Officer of Weatherden, tells us about the key strategic considerations for biopharma companies in the post-IRA era.

In this first part of a three-part series Emma Tinsley, Chief Executive Officer of Weatherden explains what the IRA is, how it affects drug pricing, and why biotech and pharma companies – including those outside the US – need to take notice.